secwatch.observer — SEC 8-K summary
======================================

Issuer:     NIKA PHARMACEUTICALS, INC (NIKA)
CIK:        0001145604
Form:       8-K
Filed at:   2022-11-15T23:59:59+00:00
Accession:  0001826466-22-000149
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Appoints Dr. Darena Stoykova Zlateva as Chief Scientific Officer effective Nov 12, 2022
--------------------------------------------------------------------------------

- Dr. Zlateva appointed CSO of Nika Pharmaceuticals effective Nov 12, 2022.
- She holds a PhD in Immunology and a medical degree; prior roles at Sofia Medical Academy and European Medical Association.
- Employment contract signed with Nika Europe Ltd., in which Nika owns a 40% stake.
- CSO will manage research projects, represent company at scientific forums, and formulate long-term research strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1145604/000182646622000149/0001826466-22-000149-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1145604/000182646622000149/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001826466-22-000149

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer